Skip to main content

Beating lockdown blues: 20 stocks from top 5 PMS schemes gave 60-90% return in 6 months

PMS schemes that gave more than 50 percent return include Nine River Capital’s AURUM Smallcap theme that delivered nearly 95 percent return in the last six months.

When India was grappling with lockdown to avoid the spread of COVID-19, portfolio managers used the dip in March to stay with possible winners of the ‘Unlock’ scenario in the small & midcap space.

 

 

Indian market might have rallied by about 30 percent in the first six months of the current financial year, but as many as 80 Portfolio Management Schemes (PMSes) outperformed the index and 20 of them rose 50-100% in the same period, according to data from PMSBazaar.com.

 

 

PMS schemes that gave more than 50 percent return include Nine River Capital’s AURUM Smallcap theme that delivered nearly 95 percent return in the last six months. Top holdings include stocks like Intellect Design, Poly Medicure, CDSL, Astra Microwave and Alkyl Amines Chemicals.

 

 

Aurum Small cap opportunities strategy is built out of 12-15 high conviction small-cap stocks with a market-cap of more than Rs 2,500 crore and an investment horizon of 3-5 years for each stock.

 

 

The other PMS schemes which rallied more than 50 percent include Equirus Securities Long Horizon Fund. The fund focuses on making concentrated bets for the long term, in high quality publicly listed Indian companies at reasonable valuations.

 

 

 


 

 

Newgen Capital’s Smallcap Emerging Fund, and ACCURACAP PICOPOWER Smallcap fund delivered more than 70 percent returns each in the last six months.

 

 

Centrum Multibagger which is a Midcap focussed fund gave over 60 percent return in the last six months. The strategy focuses on buying value stocks in the Midcap space to create value over the long term compared to its benchmark BSE500.

 

 

The top holding of this fund includes Granules, APL Apollo, Vaibhav Global, and Astral Poly Technik Ltd etc. among others.

 

 

Will the rally continue in small & midcaps?

 

 

The large part of the outperformance came from the PMS schemes which invest primarily in the broader market space. Money managers are looking for growth and after 2 years of underperformance - small & midcaps are ready to shine, suggest experts.

 

 

With the government focussing primarily on the Make in India initiative, small & midcaps are more economy-linked companies and do well when the economy does well.

 

 

The initial part of outperformance which we have seen can be attributed to liquidity, but experts feel that staying invested in companies where growth outlook remain string could turn out to be wealth creators.

 

 

“As long as the market rally is driven by liquidity, small & midcap stocks will continue to underperform. Clear visibility of earnings improvement is of utmost importance for small & midcap stocks to outperform from hereon or even sustain this rally,” Arjun Mahajan Head Institutional Business at Reliance Securities told Moneycontrol.

 

 

“Few indicators such as improvement in power demand, credit card bills, e-way bills, railway freight, etc give an indication about possible earnings recovery, prudent investors may take a while to confirm the sustainability of this recovery,” he said.

 

 

Mahajan further added that we can essentially say that a strong rally of small & midcap is very much on the cards if backed by the sustained economic recovery.


Source - Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more